COVID-19 Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D05YTN
|
|||
Drug Name |
Saracatinib
|
|||
Synonyms |
H8H; AZD-0530; Saracatinib, AZD-0530, AZD0530; N-(5-Chloro-1,3-benzodioxol-4-yl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Middle East Respiratory Syndrome (MERS) | Investigative | [1] | |
Other Indication | Metastatic colorectal cancer | Phase 2 | [2] | |
Therapeutic Class |
Antiviral Agents
|
|||
Company |
AstraZeneca
|
|||
Structure |
Download2D MOL |
|||
Formula |
C27H32ClN5O5
|
|||
Canonical SMILES |
CN1CCN(CC1)CCOC2=CC3=C(C(=C2)OC4CCOCC4)C(=NC=N3)NC5=C(C=CC6=C5OCO6)Cl
|
|||
InChI |
1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)
|
|||
InChIKey |
OUKYUETWWIPKQR-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 379231-04-6
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
15309164, 17422546, 21317858, 22676280, 41368296, 46394234, 46512739, 50076463, 52589432, 57374518, 85197643, 85246182, 92721419, 99431771, 103501598, 109692957, 118844934, 124490404, 124756929, 124950158, 125163736, 125349317, 126619163, 126660092, 126666998, 131312788, 131465100, 134339018, 134344133, 135252487, 135686054, 135686055, 135686076, 135686077, 135727436, 136368072, 136920278, 136946508, 137185244, 137275842, 141775073, 144115661, 152258141, 152344117, 160646980, 162011430, 162037380, 162200062, 163884828, 164042932
|
References | Top | |||
---|---|---|---|---|
1 | Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro. Viruses. 2018 May 24;10(6). pii: E283. | |||
2 | Phase II Study of Saracatinib (AZD0530) in Patients With Previously Treated Metastatic Colorectal Cancer. Invest New Drugs. 2015 Aug;33(4):977-84. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.